Abstract
Objective: Endometrial cancers (ECs) of copy-number high (serous-like) molecular subtype are characterized by high levels of copy-number alterations and recurrent TP53 mutations akin to high-grade serous ovarian (HGSOCs) and basal-like breast cancers, which are sensitive to platinum agents and/or PARP inhibitors. We aimed to assess whether copy-number high (serous-like) ECs show defects in homologous recombination DNA repair (HRD) akin to HGSOCs and basal-like breast cancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
